Cardiol Therapeutics | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Home
Companies
Cardiol Therapeutics

BRIEF

published on 10/28/2024 at 15:51, 23 days 20 hours ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
BRIEF

published on 10/28/2024 at 15:51, 23 days 20 hours ago

Cardiol Therapeutics lance un essai clinique de phase II/III pour la péricardite récurrente

Essai Clinique CardiolRx Péricardite Récurrente Thérapeutique Cardiol Essai MAVERIC-2
PRESS RELEASE

published on 10/28/2024 at 15:46, 23 days 20 hours ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 5 months 6 days ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
BRIEF

published on 06/14/2024 at 14:57, 5 months 6 days ago

Cardiol Therapeutics Inc reçoit une note « d'achat » mise à jour de la part de First Berlin Equity Research

Acheter Une Note CardiolRx Cardiol Thérapeutique Péricardite Récurrente Étude De Phase II
PRESS RELEASE

published on 06/14/2024 at 14:52, 5 months 6 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx
BRIEF

published on 02/27/2024 at 14:16, 8 months 22 days ago

Cardiol Therapeutics obtient la désignation de médicament orphelin par la FDA pour CardiolRx

Investissement FDA Orphan Drug Designation Cardiol Therapeutics Pericardite
BRIEF

published on 02/27/2024 at 14:16, 8 months 22 days ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
PRESS RELEASE

published on 02/27/2024 at 14:16, 8 months 22 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
PRESS RELEASE

published on 01/19/2024 at 12:41, 10 months 1 day ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential

Accesswire

Published on 11/21/2024 at 11:30, 28 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 55 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 58 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 58 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 23 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 28 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 57 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 58 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 1 hour 1 minute ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 28 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 5 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 51 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 38 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE